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Neoangiogenesis in tumours contributes to the development of blood-borne metastases, and can be evaluated by markers of
activated endothelial cells in preference to panendothelial markers. Our purpose was to document the prognostic significance of
VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 immunoexpression in breast carcinoma frozen samples (n¼905, follow-up¼11.7 years).
We observed that: (i) CD105 (P¼0.001) and Tie-2/Tek (P¼0.025) (but not VEGF-R1 and VEGF-R2) overexpression correlated
with a shorter survival, and were (Cox’s model) independent histoprognostic indicators; (ii) only CD105 marked expression
correlated (P¼0.035) with a shorter survival of node-negative patients; (iii) three markers – CD105 (P¼0.001), Tie-2/Tek
(P¼0.01), VEGF-R1 (P¼0.001), but not VEGF-R2 – correlated with metastatic risk in node-negative patients in univariate analysis;
and (iv) VEGF-R1 (P¼0.01) expression correlated with high local recurrence risk. It is concluded that CD105 and to a lesser extent
Tie-2/Tek and VEGF-R1, but not VEGF-R2 are endowed with prognostic significance that may be useful for patient monitoring,
particularly CD105 expression for selecting node-negative patients for more aggressive postsurgery therapy.
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Tumour growth and metastases require neoangiogenesis in
tumour stroma. Neoangiogenesis is a complex multistep process
including endothelial cell migration and proliferation, microvessel
differentiation and anastomosis, and extracellular matrix remodel-
ling (Folkman, 1995; Ellis and Fidler, 1996; Fox et al, 2001).
Quantification of neangiogenesis in many human solid tumours
has been reported to be a prognostic marker (Weidner et al, 1992;
Gasparini and Harris, 1995; Toi et al, 1996; Vermeulen et al, 1996),
particularly in breast carcinomas where extensive neovascularisa-
tion proved to be an indicator of poor prognosis (Horak et al,
1992).
Intratumoural microvessel density was previously evaluated
using panendothelial markers such as CD34, CD31 and von
Willebrand factor (Gasparini, 1996a; Fox et al, 2001). However,
these markers may not be specific of neoangiogenesis and may not
stain all tumour blood vessels to the same degree, and results in
terms of prognostic significance are controversial (Gasparini,
1996a,b; Vermeulen et al, 1996; Charpin et al, 1997). More
recently, markers of activated endothelial cells, such as CD105
(Seon et al, 1997; Kumar et al, 1999; Fonsatti et al, 2001), Tie-2/Tek
(Brown et al, 1995; Mustonen and Alitalo, 1995; Takahashi et al,
1995; Yokoyama et al, 2000) and VEGF (Salven et al, 1996; Peters
et al, 1998) receptors as prognostic indicators more suitable for
identifying stromal vessels resulting from tumour neoangiogen-
esis, have been reported. However, in breast carcinomas, the
prognostic significance of these markers has not been evaluated in
a large series and long-term follow-up.
Our purpose in this study was to document the variations of
VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in a large
series of breast carcinomas (n¼905), and to correlate the
immunohistochemical expression on frozen sections of these
markers with patient outcome (11.7 years follow-up) in terms of
overall survival and metastasis- and recurrence-free survival. We
specifically tried to determine whether these markers could be of
clinical relevance for selecting node-negative patients who could
benefit, after the initial surgery, from more aggressive therapy. We
also tried to determine whether these markers were equivalent or
not, and to rank them for better cost-effectiveness in routine use.
MATERIALS AND METHODS
Patients
The study included 905 patients aged 25–81 years (mean7
s.d.¼56713, 1 years) with breast carcinoma who underwent
surgery from January 1986 to December 1994. They did not receive
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ychemotherapy or hormone therapy before surgery. Axillary node
excision (n¼802) combined with wide local excision with margin
clearance of mastectomy was realised in the Department of
Oncologic Gynecology (Ho ˆpital de La Conception). All specimens
were examined by the same group of three senior pathologists
experienced in breast carcinoma diagnosis and screening (CC, LA,
SG).
The follow-up period ranged from 6 to 15 years (median 11.7
years). The records for 2001 showed that 338 patients (36.8%)
relapsed, among whom 228 died (median survival: 82 months) and
567 (63.2%) were disease free. Overall survival was calculated as
the period from surgery until date of death. Metastasis- and
recurrence-free survival were calculated as the period from surgery
until the date of first metastasis and recurrence.
The mean tumour size was 20.5713.7mm; 24% of tumours were
10mm or smaller, 42% between 10 and 20mm, 19% were more
than 20mm but less than 30mm and 15% were larger than 30mm.
Histologic examination of surgical specimens was performed on
paraffin-embedded sections stained with haematoxylin, eosin and
safranin.
Tumours were classified as ductal carcinomas (67%), lobular
carcinomas (19%) and as carcinomas of other types, including
tubular, mucinous, medullary, papillary, apocrine and mixed
(14%). They were distributed as tumour grade 1 (23%), grade 2
(52%) and grade 3 (25%). Tumour grading, initially assessed using
Scarff, Bloom and Richardson scores (Bloom and Richardson,
1957), was re-evaluated according to Elston and Ellis (1991) and
Ellis and Fidler (1996).
A mean of 14.4 (s.d.74.1) lymph nodes was found in axillary
node excision, and 449 patients (56%) were node negative.
Immunostaining procedure and quantification of
VEGF-R1, VEGF-R2, Tie-2/Tek and CD105
immunostained vessels
Fresh tissue fragments were sampled by pathologists (CC, LA, SG)
immediately after intraoperative diagnosis as described previously
(Charpin et al, 1988, 1995).
Detection of Tie-2/Tek expression and CD105 was carried out
with a polyclonal mouse anti-human Tie-2 (C-20) and anti-CD105
(E2) (Novocastra Tebu, Le Perray en Yvelines, 78610 France). The
detection of VEGF-R1 (FLT-3) and VEGF-R2 (KDR) was carried
out with mouse monoclonal antibodies (Sigma-Aldrich, 38297 St
Quentin Fallavior, France). Automated immunoperoxidase proce-
dures were performed using the Ventana Gene II device with
Ventana kits (Ventana, Strasbourg, France).
The detection of antigenic sites of oestrogen and progesterone
receptors was performed as reported previously (Charpin et al, 1988).
The microvessel count was assessed in the most vascularised
areas (hotspots) (Partanen et al, 1992; Maisonpierre et al, 1993;
Mustonen and Alitalo, 1995; Takahashi et al, 1995; Folkman and
D’Amore, 1996) using a  20 objective (1.060mm
2 field diameter)
with a Zeiss Axioplan microscope (Carl Zeiss International;
Gottingen, Germany). The mean value of the vessel count in the
four fields was retained as the final value.
With anti-Tie-2/Tek and anti-VEGF-R1 and -R2 antibodies, the
vessel labelling was incomplete and only some endothelial cells
were focally stained. Therefore, Tie-2/Tek- and VEGF-R1 and -R2-
positive staining could not be evaluated in terms of vessel count,
but only in terms of positive stromal surface semiquantitatively
assessed.
Statistical analysis
The Kaplan–Meier method was used to analyse disease-free and
overall survival rates. The difference between curves was evaluated
with the Mantel Cox test (or log-rank test) for observations
regarding censored survival or events. All computations were
carried out with NCSS 2000 statistical software (Ness, Kaysville,
UT, USA) as reported previously (Charpin et al, 1997), and the
cutoff value was validated with P-value curves (Altman et al, 1994).
RESULTS
Tie-2/Tek, VEGFR-1, VEGF-R2 and CD105 distribution in
tissue sections
Tie-2/Tek, VEGF-R1 and VEGF-R2 distribution was heterogeneous
and was observed as focally visible linear deposits in some
endothelial cells along vessel walls. The immunostained surface
was small, no more than 20% (mean¼11.58%, s.d.74.87, median
12%; mean¼8.4%, s.d.¼4.03, median¼7%; mean¼10.7%, s.d.¼4.6,
median¼11%, respectively).
CD105 were observed in most endothelial cells along the cell
membrane and/or within the cytoplasm. The staining was strong,
delineating the vessel outlines and permitted the vessel count. The
mean number of CD105-positive vessels was 13.9 (s.d.76.4) (Zeiss,
Axiophot,  20 objective).
Univariate (Kaplan–Meier and log-rank) analysis and
Tie-2/Tek, VEGF-R1, VEGF-R2 and CD105 prognostic
significance
VEGF-R1/VEGF-R2 VEGF-R1 and VEGF-R2 expressions did not
significantly correlate with the patients’ overall survival. However,
greater VEGF-R1 expression (cutoff 5%), but not of VEGF-R2,
correlated with a higher risk of metastases (P¼0.03), in particular
for node-negative patients (P¼0.001) (Table 1, Figure 1). Also,
higher expression (cutoff 5%) of VEGF-R1, but not of VEGF-R2,
correlated (P¼0.01) with a higher risk of relapse, particularly in
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Figure 1 Kaplan–Meier survivorship plot of metastasis-free survival: a
greater risk of metastasis was found (P¼0.03, not shown) for patients with
tumours in which VEGF-R1-stained surface was greater (cutoff 5%), and
more specifically in node-negative patients (p¼0.001).
Table 1 VEGF-R1 immunoexpression (cutoff¼5% stained surface) and
metastasis-free survival in node-negative patients
VEGF-R1 o5% (n¼128) VEGF-R1 X5% ( n¼321)
Metastasis  30 86
Metastasis+ 98 235
VEGFR1–R2, Tie-2, CD105 and metastasis risk
JP Dales et al
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ynode-negative patients (Figure 2, Table 2), and shorter disease-free
survival (P¼0.007). The evaluation of optimal cutoff was
determined with P curves (Altman et al, 1994).
*Tie-2/Tek The Tie-2 immunostained tumour tissue surface
(cutoff point¼7%) correlated (P¼0.025) with overall survival
(Figure 3, Table 3). Tumours with a greater (X7%) Tie-2-positive
surface were associated with poorer survival as compared to those
that exhibited a smaller Tie-2/Tek-positive surface. The evaluation
of optimal cutoff was also determined with the P curve according
to the recommendations of Altman et al (1994). However, when
node-negative patients were evaluated, Tie-2 immunoexpression
did not exhibit prognostic significance (P40.05).
In contrast, Tie-2 immunostained surface correlated with a
greater risk of early metastasis in node-negative patients (P¼0.01)
(Figure 4, Table 4) and with shorter disease-free survival (local
recurrenceþmetastases) (P¼0.003).
*CD105 The number of CD105-positive vessels (cutoff¼15)
correlated (P¼0.001) with overall survival, particularly in the
node-negative subset of patients (P¼0.035) as shown in Figure 5
and Table 5. Similarly, the number of CD105-positive vessels
(415) correlated significantly (P¼0.0002) with a higher risk of
metastases in all patients and in the subset of node-negative
patients (P¼0.001) (Figure 6).
Multivariate (Cox’s model) and prognostic significance
In multivariate analysis, a high degree of Tie-2/Tek and CD105
expression, but not of VEGF-R1-positive staining, proved to be a
prognostic indicator independent of other known histoprognostic
factors such as tumour size and grade, histological type and
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Figure 2 Kaplan–Meier survivorship plot of recurrence-free survival: a
greater risk of recurrence was found in which VEGF-R1-stained surface
within tumours was greater in node-negative patients (P¼0.01).
Table 2 VEGF-R1 immunoexpression (cutoff 5% of stained surface) and
recurrence-free survival in node-negative patients
VEGF-R1 o5% (n¼128) VEGF-R1 X5% (n¼321)
Recurrence  13 55
Recurrence+ 115 266
Overall survival
   (all patients)
Tie -
 2 < 7%
Tie - 2 > 7%
P = 0.025
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Figure 3 Kaplan–Meier survivorship plot of overall patients (but not for
node-negative patients) with breast carcinomas: a greater risk of death was
found for patients with tumours in which 7% or more of the tumour
stained surface was Tie-2/Tek positive (P¼0.025).
Table 3 Tie-2/Tek immunoexpression (cutoff¼7% of stained surface)
and overall survival
Tie-2 o7% (n¼200) Tie-2 X7% (n¼705)
Deceased 39 184
Alive 161 521
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Figure 4 Kaplan–Meier univariate analysis showing a higher risk of
metastasis in node-negative patient with tumours in which Tie-2/Tek
stained surface was larger than 7% (P¼0.01).
Table 4 Tie2/Tek immunoexpression (cutoff¼7% of stained surface)
and metastasis-free survival in node-negative patients
Tie-2 o7% (n¼333) Tie-2 X7% (n¼116)
Metastasis+ 80 36
Metastasis  253 80
VEGFR1–R2, Tie-2, CD105 and metastasis risk
JP Dales et al
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(Table 6).
DISCUSSION
Although several experimental studies have suggested that
molecules expressed by activated endothelial cells tend to produce
new vessels in human malignant tumours including breast cancer,
only one clinicopathological study (Kumar et al, 1999) has
documented the prognostic significance of these potential markers,
which could allow the selection of those node-negative patients
with early breast cancer who might benefit from more aggressive
therapy and eventually from specific antiangiogenic therapy
(Lin et al, 1997, 1998; Matsuno et al, 1999; Siemeister et al,
1999). However, although several previous reports have shown the
potential clinical relevance of these markers, whose expression
correlates with the extent of tumour vasculature and aggressive-
ness, the immunohistochemical expressions of Tie-2/Tek [Kaipai-
nen et al, 1994; Hatva et al, 1995; Salven et al, 1996; Peters et al,
1998) and of VEGF-R1 and VEGF-R2 (Yokoyama et al, 2000;
Yao et al, 2001) expression have not been well documented in the
literature, with regard to their clinicopathological relevance.
Our results show that in univariate analysis (Kaplan–Meier),
greater immunocytochemical expression of CD105 (P¼0.001) and
of Tie-2/Tek (P¼0.025) significantly correlates with a poor overall
survival, but this is not the case for VEGF-R1 and -R2. In addition,
CD105 (P¼0.035), but not Tie-2/Tek, retained a prognostic
significance in terms of overall survival in node-negative patients.
Furthermore, multivariate analysis (Cox’s/log rank) showed that
CD105 and Tie-2/Tek were independent of other current
prognostic indicators (tumour size and grade, histological type,
oestrogen and progesterone receptors). No previous reports have
shown that CD105 correlated with overall survival of node-
negative patients, but this result corroborates the study of Kumar
et al (1996) in which marked CD105 immunoexpression correlated
with overall 5-year survival of all patients. Our results show that, in
terms of overall survival, CD105 expression in breast carcinomas is
a stronger prognostic indicator as compared to Tie-2/Tek and that
VEGF-R1 and -R2 have no prognostic value.
We observed that greater expression of CD105 (P¼0.0002), Tie-
2/Tek (P¼0.0067) and VEGF-R1 (P¼0.03), but not of VEGF-R2,
correlated with greater metastatic risk. Similar correlations were
observed for node-negative patients with the three markers –
CD105 (P¼0.001), Tie-2/Tek (P¼0.01) and VEGF-R1 (P¼0.001).
Moreover, in multivariate analysis, all three were independent
indicators of metastatic risk. No previous report has documented
VEGF-R1, Tie-2/Tek and CD105 prognostic value in breast
carcinomas in terms of this risk.
Furthermore, we observed that Tie-2/Tek (P¼0.003) and VEGF-
R1 (P¼0.01), but not VEGF-R2 and CD105, correlated with early
local recurrence, and VEGF-R1 (P¼0.01) correlated with early
local recurrence in node-negative patients. This result shows
that Tie-2/Tek and VEGF-R1 are better indicators of prognosis in
terms of local relapse, in contrast to CD105 that is a better
indicator in terms of overall survival. Thus, the three markers are
of similar value in terms of metastatic risk, whereas VEGF-R2 has
no prognostic value.
The method used to evaluate microvessel density in tumours has
been diversely evaluated, likely explaining the conflicting results in
the literature (see review in Gasparini, 1996b, Charpin et al, 1997)
when antipanendothelial CD34, CD31 or von Willebrand factor
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Figure 5 Kaplan–Meier univariate analysis showing a higher risk of death
in node-negative patients (P¼0.035) with a number of CD105 positive
X15 within tumours.
Table 5 CD105 immunoexpression (cutoff of number of vessels¼15)
and survival in node-negative patients
CD105 o15 (n¼311) CD105 X15 (n¼138)
Deceased 57 37
Alive 254 101
1.00
0.75
0.50
0.25
0.00
C
u
m
u
l
a
t
i
v
e
 
p
a
t
i
e
n
t
s
Time (months)
0 12 24 36 48 60 72 84 96108120132144156168180
P = 0.001
Vessels (n < 15)
Vessels (n > 15)
Metastasis (N 
–patients)
Figure 6 Kaplan–Meier univariate analysis showing a higher risk of
metastasis in node-negative patients (P¼0.001) with a number of CD105
positive X15 within tumours.
Table 6 Multivariate analysis (Cox’s/log-rank)
Probability
level overall
survival (all
patients)
Probability
level overall
survival
(N  patients)
Probability level
metastasis-free
survival
(N  patients)
VEGF-R1 (cutoff¼5) P¼0.4540 P¼0.07631 P¼0.3812
CD105 (cutoff¼15) P¼0.038 P¼0.0041 P¼0.0366
Tie-2/Tek
(cutoff¼7)
P¼0.0273 P¼0.0924 P¼0.01808
Tumour grade P¼0.0084 P¼0.0029 P¼0.0394
ER (420%) P¼0.0224 P¼0.0781 P¼0.1774
PR (420%) P¼0.0721 P¼0.0161 P¼0.1861
Histological type P¼0.4251 P¼0.2298 P¼0.4552
Tumour size P¼0.3752 P¼0.3871 P¼0.6916
N
  patients¼node-negative patients; VEGF-R1¼Vascular endothelial growth factor
receptor 1; ER¼Oestrogen receptors; PR¼projesteron receptors.
VEGFR1–R2, Tie-2, CD105 and metastasis risk
JP Dales et al
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the present study, we investigated CD105, Tie-2/Tek and VEGF-R1
and -R2, on frozen sections (Leica 3050) with automated
immunodetection (Ventana Gene II), which constitutes optimal
conditions for antigen preservation and for procedure standardi-
sation. Our goal was firstly to determine in these optimal
conditions, the real respective value of these markers in terms of
prognosis in node-negative patients and secondly to further
develop the procedure on paraffin sections that is considered
more easy to perform routinely (work in preparation). Anti-CD105
antibodies stained the complete vessel outlines, most endothelial
cells expressing a high level of CD105. In contrast, anti-Tie-2/Tek
and likewise anti-VEGF-R1 and anti-VEGF-R2 antibodies stained
some cells or part of endothelial cells in a given vessel. Therefore,
the evaluation of CD105 as the number of vessels in ‘hotspots’
(Weidner et al, 1991, Weidner, 1995) was possible, but Tie-2/Tek,
VEGF-R1 and -R2 had to be evaluated as percentage of stained
stromal surface.
Our study shows that CD105 immunohistochemical expression
on frozen sections in breast carcinomas is an independent
prognostic indicator, better than Tie-2/Tek in terms of overall
survival for node-negative patients. CD105, Tie-2/Tek, VEGF-R1,
but not VEGF-R2 expression, also correlate with high metastatic
risk in node-negative patients. Only Tie-2/Tek and VEGF-R1
expression correlate with early local recurrence in node-negative
patients. Therefore, immunodetection of markers specific of
activated endothelial cells can be considered as potentially useful
for patient monitoring, more specifically for node-negative
patients with a poorer prognosis who might benefit from more
aggressive therapy and further antigenic therapy.
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